Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies

One of Dr. David H. “Orac” Gorski’s “Oracolytes,” a wooshipper of their Lord and Master, Lord Frackonis AstroidZeneca posted this “gem” of a comment on National Geographic’s (#NatGeo) scienceblogs . com/Insolence
——————————————————————
[A] – 4/30/2013 – #98 – Krebiozen – May.28, 2013

BTW, DJT appears to have completely unraveled on his blog, calling Orac, “a self-proclaimed “cancer researcher” ” making many other blatantly libelous statements, ranting on, and on, and on. He is clearly unwell. If anyone who knows him personally happens to read this, please get him some professional help.
——————————————————————
What does Krebiozen think Dr. David H. “Orac” Gorski is going to do since I’ve been giving the “big reveal” to some of his lies, misdirection, misinformation, and disinformation ?

Sue me for telling the truth about his lies ?
——————————————————————
[B] – 12/.5/2012 – Gorski posted:

“Indeed, one could argue that that’s why the FDA and the NCI couldn’t work with him” (Burzynski)

“They didn’t know him when they agreed to work with him in the 1990s, but as they worked with him over the course of a few years they learned his true nature, leading to an inevitable schism, which taught the NCI a lesson about the consequences of dealing with pseudoscientists”
——————————————————————
Does Gorski provide a “citation” for his claim ?

no !

Does he provide a “reference” ?

No !!

A “link” ?

NO !!!

So where did Gorski come up with this unsubstantiated claim ?

Well, it seems that Gorski has cited The Cancer Letter before without attribution
——————————————————————
[C] – 9/25/1998 – “Stanislaw Burzynski, a Polish-trained physician who initially produced antineoplastons by extracting them from human urine”
——————————————————————
[D] – 2/19/2013 – Now where have I seen a questionable statement like this before ?
——————————————————————
[E] – 1/14/2013 – Gorski posted: “As you might recall, antineoplastons are chemicals that Burzynski found in the urine of cancer patients … “
——————————————————————
[C] – 9/25/1998 – The Cancer Letter indicated that a:

trial of antineoplastons, coordinated by NCI, began at Memorial Sloan-Kettering Cancer Center, the Mayo Clinic, and the NIH Clinical Center
——————————————————————
And that the
——————————————————————
“trial, which tested Burzynski’s drug in advanced recurrent malignant glioma, accrued 9 patients and was aborted as a result of a dispute

“The dispute generated a stack of mutually recriminating memos, in which Burzynski accused the investigators of attempting to scuttle the trial, while NCI officials responded with requests that Burzynski provide the data that would back his accusations
——————————————————————
[F] – 6/23/2013 – Gorski has already proved that he does NOT have what it takes to provide the answers for the National Cancer Institute (NCI) at the National Institutes of Health (NIH)
——————————————————————
[G] – 3/30/2013

NO, Dr. Gorski, you have NOT “deconstructed his” evidence “in depth before”

Burzynski: Cancer Is Serious Business (Part I) consists of the documentary; which covered some of this, as well as the documents on the movie web-site, which you have NOT “deconstructed … in depth before”, since you
“cherry-picked” what you reviewed

Allow me
=======================================
[1] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
=======================================
[2] – 10/30/1991 – Dorothy K. Macfarlane, M.D., Head, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI) sent a 1 page letter and 5 page Memorandum to Burzynski
=======================================
[3] – 10/30/1991 – Dorothy K. Macfarlane, M.D., Head, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), sent the 5 page Memorandum re: Review of Brain Tumor Cases Treated With Antineoplastons to 6 doctors
=======================================
======================================
[4] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[5] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a 7 page letter re: Antineoplaston to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[6] – 12/2/1991 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[00] – 1991 (12/1991) – the National Cancer Institute (NCI) initiated phase II clinical trials of A10 and AS2-1 (antineoplastons)
=======================================
[7] – 10/20/1993 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institutes (NCI), Department of Health and Human Services (HHS), National Institutes of Health (NIH) sent a 4 page letter to Burzynski, which had on page 4:
=======================================
======================================
“If you are unable or unwilling to provide the antineoplastons in the near future, we will pursue alternative sources to procure the drug or its active components, and will proceed with a clinical development plan to determine whether these chemicals have activity and are beneficial for patients

20130916-121522.jpg
=======================================
[8] – 10/26/1993 – Burzynski sent a 5 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institutes (NCI), National Institutes of Health (NIH), which had on page 5
=======================================
======================================
“Your final statements that you are ready to proceed with the treatment with Antineoplastons without our participation caught me by surprise”

“It is hard to imagine that a Federal employee would consider patent infringement, thus infringing on the patent rights of thousands of our shareholders”

20130916-123059.jpg
——————————————————————
Dr. Michael A. Friedman, please take time away from being a “member of the Nominating Committee” and “director” at Forbes (#Forbes)
——————————————————————
http://www.forbes.com/profile/michael-friedman/
——————————————————————
to let us know how you planned to:

“pursue alternative sources to procure the drug (Antineoplaston) or its active components”

when Burzynski has a patent on some of “its active components” ?

I’m sure your position has nothing to do with the “hack piece” Forbes did on Burzynski where they censored my comments [000]
=======================================
[9] – 11/2/1993 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services, Public Health Services, National Institutes of Health (NIH), sent a 3 page letter to Burzynski, which had on page 3
=======================================
======================================
“Finally, if even after modifying these studies in accordance with your stated wishes, you are unwilling to supply the antineoplaston materials, please inform me as quickly as possible”

“We will then seek alternative sources of this family of molecules for proper clinical evaluation”

20130916-161534.jpg

20130916-161909.jpg

20130916-162248.jpg
Dr. Michael A. Friedman, please take time away from planning your retirement from “City of Hope”
——————————————————————
http://m.prnewswire.com/news-releases/city-of-hope-names-robert-stone-as-new-chief-executive-officer-192239551.html
——————————————————————
to let us know how you planned to:

” … then seek alternative sources of this (Antineoplaston) family of molecules for proper clinical evaluation”, when Burzynski has a patent on some of “this family of molecules”?
=======================================
[10] – 1/18/1994 – Proposal for Clinical Investigation [2 pgs.]

Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Advanced Recurrent Malignant Astrocytomas

N.C.I. Protocol # T93-0078

Pg. 2

1.0 Protocol Summary – Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Advanced Recurrent Malignant Astrocytomas

1.1 Patient Eligibility

k) Patients with tumors > 5 cm in diameter, multifocal tumors, or with leptomeningeal or with systemic metastases are excluded

1.2 Pretreatment Evaluation

1.3 Treatment Plan

20130915-192906.jpg

20130915-193228.jpg
=======================================
[11] – 3/23/1994 – Mario Sznol, M.D., Head, Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI) sent a 2 page letter to Burzynski requesting to:

1. Lower the Karnofsky performance status (KPS) from 70 to 60

2. Raise the tumor size restriction from 5 cm or less to 8 cm or less

3. Drop the exclusion of multifocal tumors and leptomeningeal spread

20130916-182546.jpg

20130916-183050.jpg
=======================================
[12] – 4/19/1994 – Burzynski sent a 2 page letter to Mario Sznol, M.D., Head, Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI), the it was his opinion that cancer patients with larger tumors should:

1. NOT be included in the protocol intended for patients with smaller tumors receiving less antineoplastons

2. Cancer patients with larger tumors should be accepted in a separate protocol for larger tumors using larger doses of antineoplastons if the existing protocol showed promise

20130916-181845.jpg

20130916-183656.jpg
=======================================
[13] – 1/31/1995 – Mark G. Malkin, M.D. sent a one page letter to John L. Lewis, M.D., Chairman, Institutional Review Board (IRB), Memorial Sloan-Kettering Cancer Center (MSKCC) re: T93-0078, RE: Protocol # 93-105, indicating that the National Cancer Institute (NCI) had changed the protocol by:

1. Lowering the Karnofsky Performance Status Score (KPS) from 70% to 60%

2. Removing the exclusion criteria so that there was “no exclusion based on tumor size, multifocality, or leptomeningeal or systemic metastases”

20130916-202002.jpg
Dr. Mark G. Malkin, the Institutional Principal Investigator, Department of Neurology, Memorial Sloan-Kettering Cancer Center (MSKCC) who sent this letter to Dr. John L. Lewis, the Protocol Chairman, can you take time from your position at the Medical College of Wisconsin
——————————————————————
http://www.mcw.edu/neurology/faculty/MarkMalkin.htm
——————————————————————
and explain why Burzynski was NOT copied on this letter since you knew from his 4/19/1994 response [12] to your 3/23/1994 letter [11] that he did NOT agree to changing the protocol?
=======================================
[14] – 3/29/1995 – Burzynski sent a 2 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), National Institutes of Health (NIH), advising him that he had learned that the protocol had been changed without his knowledge or concurrence by:

1. Lowering the Karnofsky Performance Status score (KPS) from 70% to 60%

2. Changing the eligibility criteria from tumors 5 cm or less to patients with tumors measuring over 5 cm in diameter, multiple tumors, or with leptomeningeal spread or systemic metastases

Dr. Michael A. Friedman, please take time from your Non-Executive Director appointment at Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business
——————————————————————
http://www.smith-nephew.com/news-and-media/news/michael-a-friedman-md-appointed-non-executive-director/
——————————————————————
and advise why these changes where made to the protocol, when your 3 page letter of 11/2/1993 [9] to Burzynski, advised:

Pg. 1

“[W]e will accede to all the modifications that you have stipulated”

“The changes to made to the protocol are as follows:”

1. “The dose and schedule will be modified exactly as your require”

Pg. 2

5. “The eligibility criteria will be modified to accept only patients with a Karnofsky performance status of 70-100%

20130916-215525.jpg

20130916-215909.jpg
=======================================
[15] – 4/3/1995 – Mario Sznol, M.D., Department of Health and Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI) sent a 2 page letter to Burzynski for Dr. Michael A. Friedman in response to Burzynski’s 3/29/1995 letter [14] advising:

“At the investigator’s request, the amendments to modify the eligibility restrictions for size of tumor, number of tumors, and leptomeningeal spread, and to allow entry of patients with KPS of 60, have been approved

as if the National Cancer Institute (NCI) had NOT already changed the protocol 1/31/1995 [13]

20130916-234004.jpg

20130916-235141.jpg
=======================================
[16] – 4/20/1995 – Burzynski sent a 3 page letter to Mario Sznol, M.D., Department of Health and Human Services (HHS), National Institutes of Health (NIH)

20130917-000811.jpg

20130917-001541.jpg

20130917-002052.jpg
=======================================
[17] – 4/26/1995 –

20130917-010419.jpg

20130917-010958.jpg
=======================================
[18] – 5/16/1995 – Burzynski sent a 3 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), National Institutes of Health (NIH)

20130917-003756.jpg

20130917-004513.jpg

20130917-005059.jpg
=======================================
[19] – 6/6/1995 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), sent a 3 page letter to Burzynski

20130917-012249.jpg

20130917-012808.jpg

20130917-013241.jpg
=======================================
[0000] – 7/27/1995 pg. A17 The Washington Post

In Absentia, Regulators Put on Trial by Critics

‘But researchers who have tried to duplicate Burzynski’s success have been frustrated, said Michael A. Friedman, associate director of the National Cancer Institute’s cancer therapy evaluation program in no small part because Burzynski has refused to cooperate fully”

Dr. Michael A. Friedman
——————————————————————
https://tulane.edu/presidentialsearch/michael-friedman.cfm
——————————————————————
I’m sure that Dr. David H. Gorski a/k/a “Orac” would have something to say about you commenting on a clinical trial before the final results were published, but what do you mean by:

“Burzynski has refused to cooperate fully” ?
=======================================
[20] – 8/18/1995 – CancerNet from the National Cancer Institute (NCI) [2 Pgs.]
Date Last Modified 10/1995

20130917-014814.jpg

20130917-015200.jpg
=======================================
[21] – 8/23/1995 – Robert B. Lanman, National Institutes of Health (NIH) Legal Advisor sent a one page letter to Richard A. Jaffe, which advised, in part:

“The NCI does not possess any individual patient records to provide to Dr. Burzynski”

20130917-020236.jpg
=======================================
[22] – 9/19/1995 – Dr. Michael A. Friedman sent a 2 page letter to Burzynski, which advised, in part, on page 2:

“We have no individual patient records in our possession in addition to the Theradex reports”

20130917-021234.jpg

20130917-021547.jpg
=======================================
[23] – 10/5/1995 – Robert B. Lanman, National Institutes of Health (NIH) Legal Advisor sent a one page letter to Richard A. Jaffe, which advised, in part:

“With regard to the portion of the medical record which you forwarded, the stamp does indicate that the patient was seen at the National Institutes of Health’s Clinical Center”

“We have learned that 2 patients were enrolled in the Sloan-Kettering study through the Clinical Center and hence, even though the Clinical Center did not have its own protocol, it has medical records for those 2 individuals”

20130917-022524.jpg
=======================================
[24] – 10/27/1995 – Burzynski sent a 7 page letter to Richard Klausner, M.D., Director, National Cancer Institute (NCI), National Institutes of Health (NIH)

20130917-043710.jpg

20130917-044107.jpg

20130917-044527.jpg
=======================================
[00] – 1995 (12/1995) – the National Cancer Institute (NCI) initiated phase II clinical trials of A10 and AS2-1 (antineoplastons) from 12/1991 – 12/1995
=======================================
[25] – 1/15/1998 – Robert J. Waldbillig, Ph.D.

Pharmacokinetics of Antineoplaston A10 and AS2-1 in Patients with Neoplastic Disease (2 pgs.)

20130917-035626.jpg

20130917-040010.jpg
Pg. 2

Translated into ug/mL from page 22 of 1998 FDA report on ANP

Plasma Antineoplaston Levels in Patients During Treatment

Name of Antineoplaston Ingredient
PG
IsoPG
PN

Plasma Levels (ug/mL)

Mayo Clinic (MC)
302
14 to 35
177

Burzynski
11088
2376
476

Ratio
Burzynski / MC
36 x higher
67-169 x higher
2.7 x higher

=======================================
[26] – 2/1999 Volume 74 Number 2 [3 Pgs. – Pg. 137]

Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma

Jan C. Buckner, M.D. (Mayo) Dept.Oncology
Mark G. Malkin, M.D.
Eddie Reed, M.D.
Terrence L. Cascino, M.D.
Joel M. Reid, Ph.D.
Matthew M. Ames, Ph.D.
William P.Y. Tong, Ph.D.
Silam Lam, Ph.D.
William D. Figg, Pharm.D.

Patients with
anaplastic astrocytoma

and
glioblastoma multiforme

20130917-042229.jpg

20130917-042604.jpg

20130917-043019.jpg
=======================================
National Cancer Center (NCI) at the National Institutes of Health (NIH), I do believe this is some of “the data that would back his” (Burzynski’s) “accusations”

Dr. David H. Gorski a/k/a “Orac”, enjoy !
======================================
REFERENCES [A – G]:
======================================
[A] – 4/30/2013 – Eric Merola and Stanislaw Burzynski’s secret weapon against The Skeptics™: Fabio Lanzoni (I kid you not)
——————————————————————
http://scienceblogs.com/insolence/2013/04/30/eric-merola-stanislaw-burzynskis-secret-weapon-against-the-skeptics-fabio-lanzoni/
======================================
[B] – 12/5/2012 – Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
——————————————————————
http://scienceblogs.com/insolence/2012/12/05/arrogance-of-ignorance-about-cancer/
======================================
[C] – 9/25/1998 – The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data
——————————————————————
http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/burzynski2.html
——————————————————————
The Cancer Letter, Vol. 24, No. 36, Sept.25, 1998
======================================
[D] – 2/19/2013
——————————————————————
http://m.cancer.gov/topics/CAM/antineoplastons/Patient?print=1
——————————————————————
http://m.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/antineoplaston-therapy
======================================
[E] – 1/14/2013 – The story of Seán Ó’Laighin, patient of Dr. Stanislaw Burzynski
——————————————————————
http://scienceblogs.com/insolence/2013/01/14/the-story-of-sean-olaighin-patient-of-dr-stanislaw-burzynski/
======================================
[F] – 6/23/2013 – QUESTIONS the Critics and Cynics, “The Skeptics™” do NOT want to ANSWER:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/23/questions-the-critics-and-cynics-the-skeptics-do-not-want-to-answer/
======================================
[G] – 3/20/2013 – David Gorski (@gorskon) tweeted at 12:44pm – 30 Mar 13:
======================================
=======================================
REFERENCES:
=======================================
1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/1-1991-1041991-site-visit-antineoplaston-cases/
=======================================
[2] – 1991 (10/30/1991) – Dr. Dorothy K. Macfarlane letter to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/2-1991-10301991-dr-dorothy-k-macfarlane-letter-to-burzynski/
=======================================
[3] – 1991 (10/30/1991) – Dr. Dorothy K. Macfarlane Memorandum – 10/4/1991 – site visit (5 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/3-1991-10301991-dr-dorothy-k-macfarlane-memorandum-1041991-site-visit-5-pgs/
=======================================
[4] – 1991 (10/31/1991) – Dr. Michael A. Friedman Memorandum to Dr. Bruce A. Chabner (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/4-1991-10311991-dr-michael-a-friedman-memorandum-to-dr-bruce-a-chabner-1-pg/
=======================================
[5] – 1991 (11/15/1991) – Dr. Michael J. Hawkins to Decision Network:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/5-1991-11151991-dr-michael-j-hawkins-to-decision-network/
=======================================
[6] – 1991 (12/2/1991) – NCI Decision Network Report on Antineoplastons:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/6-1991-12291-nci-decision-network-report-on-antineoplastons/
=======================================
[00] – 1991 (12/1991) – Burzynski: Managing social conflict in complementary and alternative medicine research: the case of antineoplastons:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-managing-social-conflict-in-complementary-and-alternative-medicine-research-the-case-of-antineoplastons/
=======================================
[7] – 1993 (10/20/1993) – Dr. Michael A. Friedman to Burzynski (4 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/7-1993-10201993-dr-michael-a-friedman-to-burzynski-4-pgs/
=======================================
[8] – 1993 (10/26/1993) – Burzynski to Dr. Michael A. Friedman:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/8-1993-10261993-burzynski-to-dr-michael-a-friedman/
=======================================
[000] – Dr. Peter A. Lipson (and / or his Censor(s)) is a Coward: Critiquing “A Film Producer, A Cancer Doctor, And Their Critics”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/dr-peter-a-lipson-and-or-his-censors-is-a-coward-critiquing-a-film-producer-a-cancer-doctor-and-their-critics/
=======================================
[9] – 1993 (11/2/1993) – Dr. Michael A. Friedman to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/9-1993-1121993-dr-michael-a-friedman-to-burzynski/
=======================================
[10] – 1994 (1/18/1994) – Proposal for Clinical Investigation (2 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/10-1994-1181994-proposal-for-clinical-investigation-2-pgs/
=======================================
[11] – 1994 (3/23/1994) – Dr. Mario Sznol to Burzynski [2 pgs.]:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/11-1994-3231994-dr-mario-sznol-to-burzynski-2-pgs/
=======================================
[12] – 1994 (4/19/1994) – Burzynski to Dr. Mario Sznol [2 Pgs.]:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/12-1994-4191994-burzynski-to-dr-mario-sznol-2-pgs/
=======================================
[13] – 1995 (1/31/1995) – Dr. Mark G. Malkin to Dr. John L. Lewis (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/13-1995-1311995-dr-mark-g-malkin-to-dr-john-l-lewis-1-pg/
=======================================
[14] – 1995 (3/29/1995) – Burzynski to Dr. Michael A. Friedman (2 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/14-1995-3291995-burzynski-to-dr-michael-a-friedman-2-pgs/
=======================================
[15] – 1995 (4/3/1995) – Dr. Mario Sznol to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/15-1995-431995-dr-mario-sznol-to-burzynski/
=======================================
[16] – 1995 (4/20/1995) – Burzynski to Dr. Mario Sznol;
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/16-1995-4201995-burzynski-to-dr-mario-sznol/
=======================================
[17] – 1995 (4/26/1995) (Pg. 3):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/17-1995-4261995-pg-3/
=======================================
[18] – 1995 (5/16/1995) – Burzynski to Dr. Michael A. Friedman:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/18-1995-5161995-burzynski-to-dr-michael-a-friedman/
=======================================
[19] – 1995 (6/6/1995) Dr. Michael A. Friedman to Burzynski (3 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/19-1995-661995-dr-michael-a-friedman-to-burzynski-3-pgs/
=======================================
[0000] – 7/27/1995 – 1 pg.
——————————————————————
http://legacy.library.ucsf.edu/documentStore/c/q/d/cqd59b00/Scqd59b00.pdf
——————————————————————
2 pgs.
——————————————————————
http://legacy.library.ucsf.edu/documentStore/y/i/w/yiw77d00/Syiw77d00.pdf
=======================================
[20] – 1995 (8/18/1995) – CancerNet from the National Cancer Institute (2 pgs.): CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/20-1995-8181995-cancernet-from-the-national-cancer-institute-2-pgs/
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
=======================================
=======================================
[21] – 1995 (8/23/1995) – Robert B. Lanman to Burzynski (1 Pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/21-1995-8231995-robert-b-lanman-to-burzynski-1-pg/
=======================================
[22] – 1995 (9/19/1995) – Dr. Michael A. Friedman to Burzynski (2 pgs.):]
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/22-1995-9191995-dr-michael-a-friedman-to-burzynski-2-pgs/
=======================================
[23] – 1995 (10/5/1995) – Robert B. Lanman to Burzynski (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/23-1995-1051995-robert-b-lanman-to-burzynski-1-pg/
=======================================
[24] – 1995 (10/27/1995) – Burzynski to Dr. Richard Klausner (7 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/24-1995-10271995-burzynski-to-dr-richard-klausner-7-pgs/
=======================================
=======================================

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s